Last reviewed · How we verify
Ramipril + Irbesartan
This combination lowers blood pressure by blocking angiotensin II through two complementary pathways: ACE inhibition and angiotensin II receptor antagonism.
This combination lowers blood pressure by blocking angiotensin II through two complementary pathways: ACE inhibition and angiotensin II receptor antagonism. Used for Hypertension in patients not adequately controlled on monotherapy.
At a glance
| Generic name | Ramipril + Irbesartan |
|---|---|
| Also known as | Avapro |
| Sponsor | Bristol-Myers Squibb |
| Drug class | ACE inhibitor + Angiotensin II receptor blocker combination |
| Target | ACE enzyme and AT1 angiotensin II receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ramipril is an ACE inhibitor that prevents the conversion of angiotensin I to angiotensin II, while irbesartan is an angiotensin II receptor blocker (ARB) that directly blocks AT1 receptors. Together, they provide dual inhibition of the renin-angiotensin-aldosterone system (RAAS), resulting in enhanced vasodilation, reduced aldosterone secretion, and greater blood pressure reduction than either agent alone.
Approved indications
- Hypertension in patients not adequately controlled on monotherapy
Common side effects
- Dizziness
- Cough
- Hyperkalemia
- Fatigue
- Headache
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts (PHASE3)
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- Remission Clinic in Proteinuric Chronic Nephropathies
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril + Irbesartan CI brief — competitive landscape report
- Ramipril + Irbesartan updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI